Biopharma CI is not just delayed.
It’s miscalibrated.
It’s measuring the wrong signals, asking the wrong questions, trusting the wrong voices.
Yes, it is uncomfortable to hear this from a consultant.
The real discomfort is that it already feels true.
This keynote is not a presentation.
It is a classified debrief on the failure points your team won’t see—until it’s too late:
• How “coverage” became the enemy of consequence
• How AI fluency produces coherence without truth
• How HUMINT grids now shape strategy before advisory boards convene
• Why velocity has replaced vigilance—and no one noticed
After this session, you will not look at CI the same way.
If you do, that’s the most dangerous signal of all.

While many of these headwinds are daunting, CI professionals are uniquely positioned to help their organizations anticipate market shifts, decode competitor strategy, and proactively mitigate risk. This session will explore the most critical industry challenges and offer actionable recommendations on how CI teams can deliver strategic value.

• Key elements of an excellent CI narrative with a clearly-articulated storyline, including how to win confidence as a narrator
• How a CI narrative with a clearly-articulated storyline elevates the value of CI by boosting engagement, comfort, connection, alignment and contribution
• How great storytelling “moves the needle” on critical objectives and amplifies strategic messages
• How to control your CI storyline across multi-functional stakeholders
• How to best use AI as part of this process

We will demonstrate how metrics such as market share shifts, revenue implications, and timeline effects empower faster, smarter, and more confident strategic decisions across the broader ecosystem.
Key Highlights:
• AI + expert-guided news analysis
• Clear impact quantification: market share, revenue, timelines
• Accelerated forecasting, planning, and strategic response
• Seamless integration into existing workflows, saving analyst hours

The CLIN platform provides analysis from curated oncologist commentary across social media, tracking sentiment, surfacing key conference signals, and benchmarking evolving standards of care. Combining social, scientific, and commercial data supports timely pharma decision-making.

Agentic AI changes this dynamic. It empowers AI agents to autonomously recognize meaningful patterns, proactively uncover insights, and even recommend or execute strategic actions, all within predefined goals and guardrails established by human decision-makers.

In this engaging session, David Seuss, founder and CEO of Northern Light, will share practical examples of how Agentic AI is reshaping market research and competitive intelligence in pharma, empowering organizations to move beyond reacting to market changes toward actively driving strategic decisions. Mr. Seuss will illustrate how Agentic AI:

• Accelerates strategic responses to rapidly shifting market conditions.
• Enables highly personalized insights at scale.
• Streamlines competitive intelligence through autonomous monitoring and analysis of market dynamics.

However, the development and commercialization of biosimilars differ substantially from that of generic NMEs. As a result, modern biosimilar manufacturers must stay attuned to key market trends, technological advancements, shifting dynamics, and global collaborations.
This session will shed light on the tailored competitive intelligence (CI) needs of biosimilar companies and how they diverge from traditional approaches used in innovative drug development market monitoring. It aims to help biosimilar manufacturers reassess their essential CI requirements and build a compelling case for securing the necessary budget from leadership teams.

As access to information became easier and information flow increased, CI departments have shifted their focus to “so what” – why is this new competitive information relevant to my company, focusing on insights rather than data gathering. We expect this trend to continue to evolve, from “what” to “so what” to “now what.” CI professionals need to go beyond implications to strategy recommendations. Our panel will discuss best practices for embedding strategic recommendations in all of your CI deliverables.

Furthermore, supply chain disruptions, drug pricing and reimbursement constraints, changes in regulations and policies, and volatility in biotech funding continue to impact the industry.

Meanwhile, China is emerging as a global innovation hub, with its biotech and pharmaceutical companies becoming key players in novel drug development and clinical trials with increased activity in licensing and partnership deals with international firms.

In GlobalData’s “The State of the Biopharmaceutical Industry with Spotlight on Drug Development in China” presentation, we will examine the key trends shaping the biopharmaceutical industry and the impact of pharmaceutical innovation in China.

• Regional share of total number of oncology trials and associated evolution from 2019 to 2024
• Spotlight on Europe; heat map of clinical trial growth verses a 2019 baseline – the Covid impact
• Illustrative country comparison; UK verses Romania
Analysis of data that is easily accessible that can help pharma business units and therapy area teams gain a competitive edge by conducting trials in geographies that others aren’t

This talk is to explore how CI is being repositioned as a strategic business partner driving value across the enterprise.
Objective
To provide attendees with:
• Real-world insights on how CI teams are embedding themselves into strategic decision-making
• Practical takeaways on evolving CI capabilities, processes, and influence
• Perspectives from cross-functional stakeholders on what they value most in CI as a partner
• A vision for future-proofing CI—adapting to AI, data integration, and strategic foresight needs

TRENDS: combination products to address side effects (muscle loss) & exciting new indications (MASH, addiction, etc); non Peptide GLP1s; the rise of China as a producer & innovator; new delivery systems
CHALLENGES: supply chain; manufacturing inefficiencies; geopolitics; market access; how to differentiate your GLP1.
OPPORTUNITIES: differentiation by combo products; development of new non Peptide GLP1 drug substances; drug delivery innovation; companion products in the medical device, food, nutrition, lifestyle space

This session explores how primary CI—grounded in direct, real-world insight—can inform timely course correction, future-proof decision-making, and sharpen competitive advantage across the product lifecycle from early stage evaluation to late life cycle management. What’s in it for you? Attendees will gain practical understanding of how to integrate primary CI into strategic execution and how deeper insights and how a four-pronged methodology translates to measurable impact leading to strategic advantage.

Salvador Carlucci, whose landmark 2005 Nature Biotechnology articles reshaped how biotech approached competitive intelligence, unveils the dramatic evolution of CI in the age of artificial intelligence. This provocative session bridges his original framework with cutting-edge AI capabilities, revealing unexpected synergies and disruptive opportunities. Discover how today’s most forward-thinking pharma companies are supercharging their CI methodology—from intelligence gathering to strategic decision-making—through sophisticated Agentic AI integration.

It is also resource intensive and can leave CI teams bogged down in analysis and unable to provide the strategic guidance that the business demands from them.
In this conversation between Evaluate’s CI lead, Kelly Chamberlain and J&J’s Diana Gowe, we’ll look at the value of getting peer analysis right – even in the era of AI. We’ll discuss how to identify competitive intelligence gaps, and highlight:
• Best practice for creating a peer analysis structure
• How to reduce bias from your analysis
• The strategic benefits for leaders and CI in applying learnings from peer analysis
• How to disseminate CI insights across the business